​

REGENXBIO (RGNX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RGNX Stock Forecast

REGENXBIO (RGNX) stock forecast, based on 20 Wall Street analysts, predicts a 12-month average price target of $26.00, with a high of $45.00 and a low of $12.00. This represents a 186.34% increase from the last price of $9.08.

$5 $13 $21 $29 $37 $45 High: $45 Avg: $26 Low: $12 Last Closed Price: $9.08

RGNX Stock Rating

REGENXBIO stock's rating consensus is Buy, based on 20 Wall Street analysts. The breakdown includes 1 Strong Buy (5.00%), 13 Buy (65.00%), 5 Hold (25.00%), 1 Sell (5.00%), and 0 Strong Sell (0.00%).

Buy
Total 20 0 1 5 13 1 Strong Sell Sell Hold Buy Strong Buy

RGNX Price Target Upside V Benchmarks

TypeNameUpside
StockREGENXBIO186.34%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1910
Avg Price Target$17.00$26.89$26.60
Last Closing Price$9.08$9.08$9.08
Upside/Downside87.22%196.15%192.95%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26461--11
Feb, 26461--11
Jan, 26461--11
Dec, 25461--11
Nov, 25551--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 05, 2026Judah FrommerMorgan Stanley$17.00$8.7294.95%87.22%
Feb 10, 2026H.C. Wainwright$32.00$8.92258.74%252.42%
Feb 10, 2026Brian SkorneyRobert W. Baird$27.00$8.92202.69%197.36%
Feb 10, 2026UBS$18.00$8.97100.67%98.24%
Feb 10, 2026Goldman Sachs$12.00$10.3116.39%32.16%
Jan 29, 2026Yi ChenH.C. Wainwright$34.00$11.52195.14%274.45%
Jan 27, 2026Barclays$37.00$13.41175.91%307.49%
Dec 19, 2025Stifel Nicolaus$45.00$13.51233.09%395.59%
Dec 15, 2025Mani ForooharLeerink Partners$20.00$13.8844.09%120.26%
Mar 18, 2025Leerink Partners$24.00$7.80207.69%164.32%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 05, 2026Morgan StanleyOverweightOverweighthold
Feb 10, 2026UBSOverweightOverweighthold
Jan 29, 2026H.C. WainwrightBuyBuyhold
Dec 15, 2025Leerink PartnersOutperformOutperformhold
Jan 07, 2025RBC CapitalOutperformOutperformhold
Nov 18, 2024Raymond JamesOutperformOutperformhold
Oct 10, 2024Raymond JamesBuyBuyhold
Sep 04, 2024H.C. WainwrightBuyBuyhold
Aug 05, 2024Goldman SachsUnderperformUnderperformhold
Aug 05, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.01$-6.50$-6.02$-4.59$-3.76---
Avg Forecast$3.89$-6.19$-5.52$-4.72$-0.48$-2.20$-2.54$-0.33
High Forecast$5.38$-4.39$-2.61$-4.62$0.03$-0.56$-1.53$-0.24
Low Forecast$2.74$-8.95$-6.31$-4.79$-1.24$-4.65$-3.55$-0.49
Surprise %-22.62%5.01%9.06%-2.75%683.33%---

Revenue Forecast

$50M $210M $370M $530M $690M $850M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$470.35M$112.72M$90.24M$83.33M$170.44M---
Avg Forecast$492.16M$120.42M$118.32M$86.88M$321.48M$206.30M$391.55M$582.13M
High Forecast$636.65M$161.77M$158.67M$89.69M$383.49M$212.22M$391.58M$800.54M
Low Forecast$379.75M$93.43M$99.84M$79.03M$268.89M$200.38M$391.51M$466.03M
Surprise %-4.43%-6.39%-23.73%-4.09%-46.98%---

Net Income Forecast

$-350M $-230M $-110M $10M $130M $250M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$127.84M$-280.32M$-263.49M$-227.10M$-193.88M---
Avg Forecast$170.21M$-155.31M$-263.49M$-205.87M$38.66K$-109.25M$-111.08M$-14.43M
High Forecast$235.18M$-124.25M$-210.80M$-202.25M$1.49M$-24.30M$-67.11M$-10.69M
Low Forecast$119.67M$-186.37M$-316.19M$-209.49M$-54.20M$-203.32M$-155.06M$-21.47M
Surprise %-24.89%80.49%-10.31%-501595.09%---

RGNX Forecast FAQ

Is REGENXBIO stock a buy?

REGENXBIO stock has a consensus rating of Buy, based on 20 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 13 Buy, 5 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that REGENXBIO is a favorable investment for most analysts.

What is REGENXBIO's price target?

REGENXBIO's price target, set by 20 Wall Street analysts, averages $26 over the next 12 months. The price target range spans from $12 at the low end to $45 at the high end, suggesting a potential 186.34% change from the previous closing price of $9.08.

How does REGENXBIO stock forecast compare to its benchmarks?

REGENXBIO's stock forecast shows a 186.34% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for REGENXBIO over the past three months?

  • March 2026: 36.36% Strong Buy, 54.55% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 36.36% Strong Buy, 54.55% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 36.36% Strong Buy, 54.55% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.

What is REGENXBIO’s EPS forecast?

REGENXBIO's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.2, marking a -41.49% decrease from the reported $-3.76 in 2025. Estimates for the following years are $-2.54 in 2027, and $-0.33 in 2028.

What is REGENXBIO’s revenue forecast?

REGENXBIO's average annual revenue forecast for its fiscal year ending in December 2026 is $206.3M, reflecting a 21.04% increase from the reported $170.44M in 2025. The forecast for 2027 is $391.55M, and $582.14M for 2028.

What is REGENXBIO’s net income forecast?

REGENXBIO's net income forecast for the fiscal year ending in December 2026 stands at $-109M, representing a -43.65% decrease from the reported $-194M in 2025. Projections indicate $-111M in 2027, and $-14.432M in 2028.